Hello everyone,
My father recently had routine bloodwork that came back abnormal so further labs were drawn showing:
IgG 1936 mg/dL (694-1618) High
IgA 54 mg/dL (81 - 463) Low
IgM 10 mg/dL (48-271) Low
Kappa 73 mg/dL (74 - 295) Low
Lambda 580 mg/dL (32 - 156) High
Kappa/Lambda ratio 0.1 (1.3 - 2.7) Low
M Spike 1.7 g/dL
Note: Restricted band / M-Spike migrating in gamma globulin region
Beta 2 Microglobulin 2.94 mg/L (< or = 2.51) High
Urine immonufixation was normal.
My father has been referred to an oncologist for further evaluation. I am a nurse and I have been doing some reading about these lab results and MGUS, smoldering myeloma, and multiple myeloma.
My question is: can the beta 2 microglobulin be elevated in MGUS? The reading I have done about it talks about how it is somewhat of a marker for myeloma severity. However, do patients have elevated beta 2 microglobulin with MGUS or is it exclusive to multiple myeloma / smoldering myeloma?
This is of course something my father and I will discuss with his physician, but I was curious and couldn't find a clear answer anywhere.
Thank you in advance.
Forums
4 posts
• Page 1 of 1
-
Helen521 - Who do you know with myeloma?: father (Smoldering)
- When were you/they diagnosed?: Sept 2016
- Age at diagnosis: 65
Re: Beta 2 microglobulin and MGUS
Yes, MGUS patients can have elevated B2M levels. See this article:
Garewal, H., et al, "Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders," Journal of Clinical Oncology, January 1984 (abstract)
Abstract:
Serum beta 2-microglobulin (beta 2-M) measurements were carried out in 97 patients with monoclonal plasma cell disorders. Twenty-six (87%) of 30 patients with monoclonal gammopathy of undetermined significance (MGUS) had increased beta 2-M levels and serial follow-up in seven patients showed a progressive increase with time. Of the 63 patients with active myeloma, pretreatment serum beta 2-M values were available in 25 for correlation with pretreatment stage. Stage III beta 2-M levels were significantly higher than stages I and II (p less than 0.001). Four patients with smoldering myeloma had beta 2-M values similar to stage I disease. There was, therefore, excellent correlation between beta 2-M and myeloma tumor burden. Levels of beta 2-M decreased with response to chemotherapy induction and low levels in stable remission (plateau phase) were associated with unusually good prognosis. Median survival for stage III patients in stable remission with low serum beta 2-M was greater than 48 months. Conversely, at relapse very high beta 2-M levels were associated with a very fulminant and refractory course. Serum beta 2-M, therefore, appears to be an extremely useful marker in initial stratification and follow-up of myeloma patients.
Garewal, H., et al, "Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders," Journal of Clinical Oncology, January 1984 (abstract)
Abstract:
Serum beta 2-microglobulin (beta 2-M) measurements were carried out in 97 patients with monoclonal plasma cell disorders. Twenty-six (87%) of 30 patients with monoclonal gammopathy of undetermined significance (MGUS) had increased beta 2-M levels and serial follow-up in seven patients showed a progressive increase with time. Of the 63 patients with active myeloma, pretreatment serum beta 2-M values were available in 25 for correlation with pretreatment stage. Stage III beta 2-M levels were significantly higher than stages I and II (p less than 0.001). Four patients with smoldering myeloma had beta 2-M values similar to stage I disease. There was, therefore, excellent correlation between beta 2-M and myeloma tumor burden. Levels of beta 2-M decreased with response to chemotherapy induction and low levels in stable remission (plateau phase) were associated with unusually good prognosis. Median survival for stage III patients in stable remission with low serum beta 2-M was greater than 48 months. Conversely, at relapse very high beta 2-M levels were associated with a very fulminant and refractory course. Serum beta 2-M, therefore, appears to be an extremely useful marker in initial stratification and follow-up of myeloma patients.
-
Multibilly - Name: Multibilly
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: Smoldering, Nov, 2012
Re: Beta 2 microglobulin and MGUS
Thank you for the info! This is a bit overwhelming while we wait to get answers, so I do appreciate your input.
-
Helen521 - Who do you know with myeloma?: father (Smoldering)
- When were you/they diagnosed?: Sept 2016
- Age at diagnosis: 65
Re: Beta 2 microglobulin and MGUS
Hi!
I have a similar question.
I had an M-spike of 0.2, which seems pretty low. I was sent to a hematologist and he is doing a lot more lab work and full skeletal survey. My beta 2 microglobulin is 2.3 mg/l and I'm wondering if that is significant and if it means anything.
I have a similar question.
I had an M-spike of 0.2, which seems pretty low. I was sent to a hematologist and he is doing a lot more lab work and full skeletal survey. My beta 2 microglobulin is 2.3 mg/l and I'm wondering if that is significant and if it means anything.
4 posts
• Page 1 of 1